Aclaris Therapeutics, Inc. - Special Call Transcript
Good day, ladies and gentlemen, and welcome to the Aclaris presents top line data from AUAT-201 Oral phase II trials. (Operator Instructions) As a reminder, this conference call may be recorded for replay purposes. It is now my pleasure to hand the conference to Ms. Kamil Ali-Jackson. Ma'am, you may begin.
Thank you. I'm Kamil Ali-Jackson, Chief Legal Officer for Aclaris. Please note that earlier today, Aclaris issued a press release announcing results from AUAT-201 Oral phase II clinical trial for ATI-501, an investigational oral Janus Kinase (JAK)1/3 inhibitor. For those of you who have not seen the press release yet, you will find the release posted in the Investors section of our website at www.aclaristx.com. Joining me today for the call are Dr. Neal Walker, President and Chief Executive Officer; Dr. Stuart Shanler, our Chief Scientific Officer; and Dr.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investorsā 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |